Optimize for Outcomes with Omnipod® 5

Omnipod 5 real-world evidence demonstrated over

Time in range (TIR) with optimized settings¹

1. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.

Did you know?

53% of Omnipod 5 users not achieving glycemic targets do not frequently use the lowest Target Glucose setting of 110 mg/dL²

TIR improvement as Target Glucose setting is lowered to 110 mg/dL

Real-world users increased TIR by up to 12% by switching from the highest to the lowest Target Glucose setting with no clinically meaningful impact on time below range³.

Bar chart demonstrating that higher starting glucose targets (150 mg/dL) lead to the biggest TIR improvement

Data shown as median. Results shown for users with ≥14 days of data and sufficient CGM data (users with ≥75% of days with ≥220 readings). *p<0.05 comparing TIR in the first target period to the second period at the 110 mg/dL target.

Real-world insights to maximize TIR with Omnipod 5

Real-world data demonstrated the following settings can help to achieve optimal TIR¹

	Setting	Optimized Value	Impact
1	Target Glucose	110 mg/dL (lowest setting)	Maximizes algorithm responsiveness
2	Insulin to Carb Ratio	≤350/TDI	Optimize postprandial glycemia
3	Correction Factor	≤1500/TDI	Improve efficacy of user-initiated corrections

Leverage optimized settings for your Omnipod 5 patients: Small changes can lead to big improvements.

Learn more about
personalizing settings

“Practical considerations for using the Omnipod 5 Automated Insulin Delivery System:
Clinical experience from the United States and Europe”

Download Publication

In Diabetes, Obesity and Metabolism Volume 27, Issue 6 Jun 2025

By: Cari Berget, et al.

The authors provide a series of clinical vignettes illustrating advanced cases related to the initiation and ongoing optimization of insulin therapy using the Omnipod 5 system, including how to personalize settings and optimize glycemic outcomes in a variety of clinical circumstances.

If you are unable to find the information you are seeking or require additional information, please contact us.

References:

1. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.

2. Insulet data on file. 2025. Retrospective analysis including 103,369 T1D users with TIR (3.9-10.0 mmol/L or 70-180 mg/dL) <70%. 54,365 (53%) did not use the 110mg/dL (6.1mmol/L) target as their average glucose target setting. RF-062025-00038

3. Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with T1D aged 2+, and 58 people with T2D aged 18+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved 11.8% (p<0.05), and median time <70 mg/dL +0.23% (p<0.05) for people with T1D. Median time in Range (70-180 mg/dL) improved 10.4% (p<0.05), and median time < 70 mg/dL +0.04% (non-significant) for people with T2D. Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Data on File. 05.15.25. RF-042025-00013

Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for important safety information.

INS-OHS-06-2025-00020 V3.0